VPRIV (velaglucerase alfa), an approved enzyme replacement therapy (ERT) for Gaucher disease, appears to be safe and effective in children younger than 4 — an age group not included in the clinical trials that supported the treatment’s approval. That’s according to a new U.S. real-world study that…
Read more
Now that we’re in the month of November and the leaves and weather have shifted to fall, I’ve been reflecting on the idea of transitioning through seasons. Time often feels linear, but the beauty of seasons is that they bring cycles of change: moments of growth, transition, and movement. I…
Elelyso (taliglucerase alfa) provides long-term clinical benefits for people with type 1 Gaucher disease, with a favorable safety profile, according to real-world data from a 10-year study in Albania. The treatment was effective in both patients starting therapy for the first time and…
